While few question the necessity of the Defense Department's investments in protecting military personnel from biological threats, the scale and type of projects is a source of considerable controversy, as shown by the Pentagon's latest push into vaccine manufacturing.
Private equity outfit JLL Partners bet big on contract manufacturing last week with its $2.6 billion deal to combine Dutch Royal DSM with its portfolio CMO Patheon, and the fund's co-founder said the company's not done yet.
Pharmacyclics and Johnson & Johnson are riding high on an accelerated approval for the blockbuster hopeful Imbruvica, and now they've tapped Catalent to aid in commercial manufacturing and ongoing clinical trials for the cancer drug.
Deal-happy CMO Capsugel hasn't forgotten about its latest acquiree, planning to invest $20 million in Bend Research's spray-dried dispersion technology just a month after closing the buyout deal.
With three year's of back-and-forth with the FDA under its belt, contract drug developer AMRI has finally closed the book on an agency warning letter tied to its Burlington, MA, plant, ending a protracted saga that has cost the company millions.
In August, a Wall Street analyst placed a headline-grabbing $0 price target on the stock of struggling cancer vaccine manufacturer Dendreon. Now, Dendreon has reportedly hired JP Morgan Chase to find someone who sees more value in the company and is willing to back their belief by acquiring the business.
Dutch CMO PharmaCell has inked a deal with the struggling Dendreon to manufacture its prostate cancer drug Provenge in Europe.
Germany's Aenova has sealed a deal for contract development and manufacturing outfit Haupt Pharma, a buyout that expands its capabilities and global reach.
After years of regulatory woes and drug shortages, Boehringer Ingelheim is calling it quits for Ben Venue, planning to shut down its contract manufacturing arm by year's end and lay off about 1,100 workers.
Counting on a boom in the Asian demand for injectables, contract manufacturer West Pharmaceutical Services has opened the doors on a nearly 40,000-square-foot facility.